Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation-positive melanoma receiving adjuvant vemurafenib.
暂无分享，去创建一个
D. Schadendorf | P. Ascierto | M. Mandalà | P. Rutkowski | L. Demidov | K. Lewis | A. Mackiewicz | M. Wongchenko | A. Guminski | A. D. di Giacomo | I. Bondarenko | B. Simmons | Y. Yan | C. Herbert | C. Ye | G. Hooper | G. Goodman | A. D. Di Giacomo